Bausch Health Companies (BHC) Asset Writedowns and Impairment (2009 - 2025)
Bausch Health Companies (BHC) reported Asset Writedowns and Impairment of $7.0 million for Q4 2025, down 69.57% on a YoY basis from $23.0 million in Q4 2024, and up 600.0% sequentially from $1.0 million in Q3 2025.
Bausch Health Companies (BHC) Asset Writedowns and Impairment (2009 - 2025) Analysis & Trends
Bausch Health Companies (BHC) has 12 years of Asset Writedowns and Impairment data on file, last reported at $7.0 million in Q4 2025.
- For the quarter ending Q4 2025, Asset Writedowns and Impairment fell 69.57% year-over-year to $7.0 million; the trailing twelve-month figure through Dec 2025 stood at $8.0 million (down 72.41% YoY), and the FY2025 full-year result was $8.0 million, down 72.41% from the prior year.
- Asset Writedowns and Impairment advanced to $7.0 million in Q4 2025, from $1.0 million in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $148.0 million in Q1 2021 to a low of $1.0 million in Q3 2022.
- A 5-year average of $22.7 million and a median of $8.0 million in 2022 frame the typical range for Asset Writedowns and Impairment.
- Across the five-year window, Asset Writedowns and Impairment soared 4600.0% in 2021 and tumbled 94.59% in 2022, its largest moves.
- Tracing BHC's Asset Writedowns and Impairment over 5 years: stood at $21.0 million in 2021, then tumbled by 95.24% to $1.0 million in 2022, then jumped by 300.0% to $4.0 million in 2023, then soared by 475.0% to $23.0 million in 2024, then plunged by 69.57% to $7.0 million in 2025.
- Business Quant data shows BHC's Asset Writedowns and Impairment at $7.0 million in Q4 2025, $1.0 million in Q3 2025, and $23.0 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn |
| 3 | Zoetis | 32.68 Bn | 30.74 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.63 Bn | 23.57 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.16 Bn | 21.01 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - |
| 7 | Viatris | 20.34 Bn | 18.54 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn |
| 10 | Bausch Health Companies | 1.70 Bn | 387.97 Mn | 2.52 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.00 Mn |
| Dec 31, 2025 | 7.00 Mn |
| Sep 30, 2025 | 1.00 Mn |
| Sep 30, 2025 | 1.00 Mn |
| Dec 31, 2024 | 23.00 Mn |
| Dec 31, 2024 | 23.00 Mn |
| Jun 30, 2024 | 5.00 Mn |
| Jun 30, 2024 | 5.00 Mn |
| Mar 31, 2024 | 1.00 Mn |
| Mar 31, 2024 | 1.00 Mn |
| Sep 30, 2023 | 4.00 Mn |
| Sep 30, 2023 | 4.00 Mn |
| Jun 30, 2023 | 37.00 Mn |
| Jun 30, 2023 | 37.00 Mn |
| Mar 31, 2023 | 13.00 Mn |
| Mar 31, 2023 | 13.00 Mn |
| Sep 30, 2022 | 1.00 Mn |
| Sep 30, 2022 | 1.00 Mn |
| Jun 30, 2022 | 6.00 Mn |
| Jun 30, 2022 | 6.00 Mn |